How Big Will the SpaceX IPO Be?
Operated up to now as a private business, SpaceX will…
Buy
69
FOLD Quote, Financials, Valuation and Earnings
Last price:
$14.29
Seasonality move
:
-8.49%
Day range:
$14.26 - $14.30
52-week range:
$5.51 - $14.38
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
7.32x
P/B ratio:
19.15x
Volume:
24.4M
Avg. volume:
9.6M
1-year change:
45.47%
Market cap:
$4.4B
Revenue:
$528.3M
EPS (TTM):
-$0.04
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
FOLD
Amicus Therapeutics, Inc.
|
$185M | $0.18 | 29.62% | 267.32% | $14.50 |
|
BMRN
BioMarin Pharmaceutical, Inc.
|
$834.6M | $0.71 | 11.96% | 37.26% | $90.74 |
|
CRMD
CorMedix, Inc.
|
$127M | $0.81 | 178.34% | 90.44% | $14.86 |
|
KROS
Keros Therapeutics, Inc.
|
$3.7M | -$0.44 | 20.4% | -61.58% | $23.38 |
|
KRYS
Krystal Biotech, Inc.
|
$105.3M | $1.61 | 31.59% | 41.28% | $289.10 |
|
MNKD
MannKind Corp.
|
$99.9M | $0.03 | 30.05% | 17.65% | $9.61 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
FOLD
Amicus Therapeutics, Inc.
|
$14.30 | $14.50 | $4.4B | -- | $0.00 | 0% | 7.32x |
|
BMRN
BioMarin Pharmaceutical, Inc.
|
$58.13 | $90.74 | $11.2B | 21.78x | $0.00 | 0% | 3.68x |
|
CRMD
CorMedix, Inc.
|
$7.69 | $14.86 | $605.9M | 3.75x | $0.00 | 0% | 2.59x |
|
KROS
Keros Therapeutics, Inc.
|
$17.57 | $23.38 | $535.3M | 11.39x | $0.00 | 0% | 2.89x |
|
KRYS
Krystal Biotech, Inc.
|
$272.74 | $289.10 | $7.9B | 40.91x | $0.00 | 0% | 21.81x |
|
MNKD
MannKind Corp.
|
$5.78 | $9.61 | $1.8B | 61.36x | $0.00 | 0% | 5.69x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
FOLD
Amicus Therapeutics, Inc.
|
65.77% | -0.293 | 18.22% | 1.91x |
|
BMRN
BioMarin Pharmaceutical, Inc.
|
9.17% | -0.896 | 5.87% | 2.84x |
|
CRMD
CorMedix, Inc.
|
1.16% | 2.679 | 0.48% | 1.60x |
|
KROS
Keros Therapeutics, Inc.
|
2.42% | -0.669 | 2.71% | 28.93x |
|
KRYS
Krystal Biotech, Inc.
|
0.83% | -0.723 | 0.19% | 9.43x |
|
MNKD
MannKind Corp.
|
124.56% | -0.068 | 13.7% | 2.54x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
FOLD
Amicus Therapeutics, Inc.
|
$147.7M | $34.3M | -2.18% | -7.02% | 20.27% | $35.3M |
|
BMRN
BioMarin Pharmaceutical, Inc.
|
$641.8M | $184.9M | 8.12% | 8.99% | 23.5% | $334.9M |
|
CRMD
CorMedix, Inc.
|
$93.1M | $51.3M | 94.54% | 95.25% | 49.24% | $30.4M |
|
KROS
Keros Therapeutics, Inc.
|
$13.9M | -$15.4M | 9.66% | 9.94% | -107.87% | $3.1M |
|
KRYS
Krystal Biotech, Inc.
|
$92.1M | $41.4M | 19.74% | 19.91% | 42.31% | $38M |
|
MNKD
MannKind Corp.
|
$61.9M | $18.8M | 24.75% | -- | 22.86% | $22.4M |
Amicus Therapeutics, Inc. vs. Competitors
-
Which has Higher Returns FOLD or BMRN?
BioMarin Pharmaceutical, Inc. has a net margin of 10.24% compared to Amicus Therapeutics, Inc.'s net margin of -3.91%. Amicus Therapeutics, Inc.'s return on equity of -7.02% beat BioMarin Pharmaceutical, Inc.'s return on equity of 8.99%.
Company Gross Margin Earnings Per Share Invested Capital FOLDAmicus Therapeutics, Inc.87.38% $0.06 $673.2M BMRNBioMarin Pharmaceutical, Inc.81.58% -$0.16 $6.7B -
What do Analysts Say About FOLD or BMRN?
Amicus Therapeutics, Inc. has a consensus price target of $14.50, signalling upside risk potential of 1.4%. On the other hand BioMarin Pharmaceutical, Inc. has an analysts' consensus of $90.74 which suggests that it could grow by 56.1%. Given that BioMarin Pharmaceutical, Inc. has higher upside potential than Amicus Therapeutics, Inc., analysts believe BioMarin Pharmaceutical, Inc. is more attractive than Amicus Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings FOLDAmicus Therapeutics, Inc.0 7 0 BMRNBioMarin Pharmaceutical, Inc.14 6 0 -
Is FOLD or BMRN More Risky?
Amicus Therapeutics, Inc. has a beta of 0.381, which suggesting that the stock is 61.857% less volatile than S&P 500. In comparison BioMarin Pharmaceutical, Inc. has a beta of 0.256, suggesting its less volatile than the S&P 500 by 74.362%.
-
Which is a Better Dividend Stock FOLD or BMRN?
Amicus Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BioMarin Pharmaceutical, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Amicus Therapeutics, Inc. pays -- of its earnings as a dividend. BioMarin Pharmaceutical, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios FOLD or BMRN?
Amicus Therapeutics, Inc. quarterly revenues are $169.1M, which are smaller than BioMarin Pharmaceutical, Inc. quarterly revenues of $786.8M. Amicus Therapeutics, Inc.'s net income of $17.3M is higher than BioMarin Pharmaceutical, Inc.'s net income of -$30.7M. Notably, Amicus Therapeutics, Inc.'s price-to-earnings ratio is -- while BioMarin Pharmaceutical, Inc.'s PE ratio is 21.78x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amicus Therapeutics, Inc. is 7.32x versus 3.68x for BioMarin Pharmaceutical, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income FOLDAmicus Therapeutics, Inc.7.32x -- $169.1M $17.3M BMRNBioMarin Pharmaceutical, Inc.3.68x 21.78x $786.8M -$30.7M
-
Which has Higher Returns FOLD or CRMD?
CorMedix, Inc. has a net margin of 10.24% compared to Amicus Therapeutics, Inc.'s net margin of 49.9%. Amicus Therapeutics, Inc.'s return on equity of -7.02% beat CorMedix, Inc.'s return on equity of 95.25%.
Company Gross Margin Earnings Per Share Invested Capital FOLDAmicus Therapeutics, Inc.87.38% $0.06 $673.2M CRMDCorMedix, Inc.89.26% $1.26 $378.5M -
What do Analysts Say About FOLD or CRMD?
Amicus Therapeutics, Inc. has a consensus price target of $14.50, signalling upside risk potential of 1.4%. On the other hand CorMedix, Inc. has an analysts' consensus of $14.86 which suggests that it could grow by 93.2%. Given that CorMedix, Inc. has higher upside potential than Amicus Therapeutics, Inc., analysts believe CorMedix, Inc. is more attractive than Amicus Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings FOLDAmicus Therapeutics, Inc.0 7 0 CRMDCorMedix, Inc.4 0 0 -
Is FOLD or CRMD More Risky?
Amicus Therapeutics, Inc. has a beta of 0.381, which suggesting that the stock is 61.857% less volatile than S&P 500. In comparison CorMedix, Inc. has a beta of 1.388, suggesting its more volatile than the S&P 500 by 38.76%.
-
Which is a Better Dividend Stock FOLD or CRMD?
Amicus Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CorMedix, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Amicus Therapeutics, Inc. pays -- of its earnings as a dividend. CorMedix, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios FOLD or CRMD?
Amicus Therapeutics, Inc. quarterly revenues are $169.1M, which are larger than CorMedix, Inc. quarterly revenues of $104.3M. Amicus Therapeutics, Inc.'s net income of $17.3M is lower than CorMedix, Inc.'s net income of $108.6M. Notably, Amicus Therapeutics, Inc.'s price-to-earnings ratio is -- while CorMedix, Inc.'s PE ratio is 3.75x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amicus Therapeutics, Inc. is 7.32x versus 2.59x for CorMedix, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income FOLDAmicus Therapeutics, Inc.7.32x -- $169.1M $17.3M CRMDCorMedix, Inc.2.59x 3.75x $104.3M $108.6M
-
Which has Higher Returns FOLD or KROS?
Keros Therapeutics, Inc. has a net margin of 10.24% compared to Amicus Therapeutics, Inc.'s net margin of -51.05%. Amicus Therapeutics, Inc.'s return on equity of -7.02% beat Keros Therapeutics, Inc.'s return on equity of 9.94%.
Company Gross Margin Earnings Per Share Invested Capital FOLDAmicus Therapeutics, Inc.87.38% $0.06 $673.2M KROSKeros Therapeutics, Inc.97.23% -$0.18 $721M -
What do Analysts Say About FOLD or KROS?
Amicus Therapeutics, Inc. has a consensus price target of $14.50, signalling upside risk potential of 1.4%. On the other hand Keros Therapeutics, Inc. has an analysts' consensus of $23.38 which suggests that it could grow by 33.04%. Given that Keros Therapeutics, Inc. has higher upside potential than Amicus Therapeutics, Inc., analysts believe Keros Therapeutics, Inc. is more attractive than Amicus Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings FOLDAmicus Therapeutics, Inc.0 7 0 KROSKeros Therapeutics, Inc.6 4 0 -
Is FOLD or KROS More Risky?
Amicus Therapeutics, Inc. has a beta of 0.381, which suggesting that the stock is 61.857% less volatile than S&P 500. In comparison Keros Therapeutics, Inc. has a beta of 0.857, suggesting its less volatile than the S&P 500 by 14.332%.
-
Which is a Better Dividend Stock FOLD or KROS?
Amicus Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Keros Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Amicus Therapeutics, Inc. pays -- of its earnings as a dividend. Keros Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios FOLD or KROS?
Amicus Therapeutics, Inc. quarterly revenues are $169.1M, which are larger than Keros Therapeutics, Inc. quarterly revenues of $14.3M. Amicus Therapeutics, Inc.'s net income of $17.3M is higher than Keros Therapeutics, Inc.'s net income of -$7.3M. Notably, Amicus Therapeutics, Inc.'s price-to-earnings ratio is -- while Keros Therapeutics, Inc.'s PE ratio is 11.39x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amicus Therapeutics, Inc. is 7.32x versus 2.89x for Keros Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income FOLDAmicus Therapeutics, Inc.7.32x -- $169.1M $17.3M KROSKeros Therapeutics, Inc.2.89x 11.39x $14.3M -$7.3M
-
Which has Higher Returns FOLD or KRYS?
Krystal Biotech, Inc. has a net margin of 10.24% compared to Amicus Therapeutics, Inc.'s net margin of 81.15%. Amicus Therapeutics, Inc.'s return on equity of -7.02% beat Krystal Biotech, Inc.'s return on equity of 19.91%.
Company Gross Margin Earnings Per Share Invested Capital FOLDAmicus Therapeutics, Inc.87.38% $0.06 $673.2M KRYSKrystal Biotech, Inc.94.21% $2.66 $1.1B -
What do Analysts Say About FOLD or KRYS?
Amicus Therapeutics, Inc. has a consensus price target of $14.50, signalling upside risk potential of 1.4%. On the other hand Krystal Biotech, Inc. has an analysts' consensus of $289.10 which suggests that it could grow by 6%. Given that Krystal Biotech, Inc. has higher upside potential than Amicus Therapeutics, Inc., analysts believe Krystal Biotech, Inc. is more attractive than Amicus Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings FOLDAmicus Therapeutics, Inc.0 7 0 KRYSKrystal Biotech, Inc.11 0 0 -
Is FOLD or KRYS More Risky?
Amicus Therapeutics, Inc. has a beta of 0.381, which suggesting that the stock is 61.857% less volatile than S&P 500. In comparison Krystal Biotech, Inc. has a beta of 0.493, suggesting its less volatile than the S&P 500 by 50.719%.
-
Which is a Better Dividend Stock FOLD or KRYS?
Amicus Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Krystal Biotech, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Amicus Therapeutics, Inc. pays -- of its earnings as a dividend. Krystal Biotech, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios FOLD or KRYS?
Amicus Therapeutics, Inc. quarterly revenues are $169.1M, which are larger than Krystal Biotech, Inc. quarterly revenues of $97.8M. Amicus Therapeutics, Inc.'s net income of $17.3M is lower than Krystal Biotech, Inc.'s net income of $79.4M. Notably, Amicus Therapeutics, Inc.'s price-to-earnings ratio is -- while Krystal Biotech, Inc.'s PE ratio is 40.91x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amicus Therapeutics, Inc. is 7.32x versus 21.81x for Krystal Biotech, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income FOLDAmicus Therapeutics, Inc.7.32x -- $169.1M $17.3M KRYSKrystal Biotech, Inc.21.81x 40.91x $97.8M $79.4M
-
Which has Higher Returns FOLD or MNKD?
MannKind Corp. has a net margin of 10.24% compared to Amicus Therapeutics, Inc.'s net margin of 9.72%. Amicus Therapeutics, Inc.'s return on equity of -7.02% beat MannKind Corp.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital FOLDAmicus Therapeutics, Inc.87.38% $0.06 $673.2M MNKDMannKind Corp.75.4% $0.03 $181.4M -
What do Analysts Say About FOLD or MNKD?
Amicus Therapeutics, Inc. has a consensus price target of $14.50, signalling upside risk potential of 1.4%. On the other hand MannKind Corp. has an analysts' consensus of $9.61 which suggests that it could grow by 66.28%. Given that MannKind Corp. has higher upside potential than Amicus Therapeutics, Inc., analysts believe MannKind Corp. is more attractive than Amicus Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings FOLDAmicus Therapeutics, Inc.0 7 0 MNKDMannKind Corp.8 0 0 -
Is FOLD or MNKD More Risky?
Amicus Therapeutics, Inc. has a beta of 0.381, which suggesting that the stock is 61.857% less volatile than S&P 500. In comparison MannKind Corp. has a beta of 0.839, suggesting its less volatile than the S&P 500 by 16.131%.
-
Which is a Better Dividend Stock FOLD or MNKD?
Amicus Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. MannKind Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Amicus Therapeutics, Inc. pays -- of its earnings as a dividend. MannKind Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios FOLD or MNKD?
Amicus Therapeutics, Inc. quarterly revenues are $169.1M, which are larger than MannKind Corp. quarterly revenues of $82.1M. Amicus Therapeutics, Inc.'s net income of $17.3M is higher than MannKind Corp.'s net income of $8M. Notably, Amicus Therapeutics, Inc.'s price-to-earnings ratio is -- while MannKind Corp.'s PE ratio is 61.36x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amicus Therapeutics, Inc. is 7.32x versus 5.69x for MannKind Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income FOLDAmicus Therapeutics, Inc.7.32x -- $169.1M $17.3M MNKDMannKind Corp.5.69x 61.36x $82.1M $8M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Where Will ISRG Stock Be in 5 Years?
Intuitive Surgical (NASDAQ:ISRG) is the innovative medical tech business behind…
Is Kratos Stock a Good Investment?
UAV and hypersonic system defense contractor Kratos (NASDAQ:KTOS) has swung…
Stock Ideas
Buy
56
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
61
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
53
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 30x
Alerts
Sell
40
BILL alert for Feb 7
Bill Holdings, Inc. [BILL] is up 37.11% over the past day.
Buy
75
PRLB alert for Feb 7
Proto Labs, Inc. [PRLB] is up 28.33% over the past day.
Sell
30
MSTR alert for Feb 7
Strategy, Inc. [MSTR] is up 26.08% over the past day.
